Weight-loss drug may also activate brown fat, mouse study finds
A study in obese mice found that tirzepatide, sold as Mounjaro and Zepbound, switched on brown adipose tissue, a type of fat that burns energy. This suggests the drug may affect metabolism in ways beyond simply reducing food intake. If the same effect occurs in humans, it could help explain the medication's benefits and guide broader treatments for obesity and diabetes.
Tirzepatide, marketed as Mounjaro and Zepbound, acts on both GIP and GLP-1 hormone receptors. It is approved for type 2 diabetes that is not well controlled and for weight management in certain adults with obesity or overweight plus related conditions. Much of its weight-loss effect has been attributed to lower food intake.
In obese mice on a high-fat diet, researchers compared treated animals with untreated mice given identical amounts of food. This design helped separate drug-specific metabolic changes from those caused by eating less. The drug switched on brown adipose tissue, which uses energy rather than mainly storing it, and increased metabolism-beneficial batokines.
If the brown-fat effect translates to humans, people with obesity or type 2 diabetes could benefit from a clearer understanding of how tirzepatide works beyond appetite reduction. Clinicians may eventually use such insights to guide broader metabolic treatments. Still, mouse findings often do not carry over, so the societal impact remains uncertain. Access, cost, and prescribing decisions may influence who ultimately benefits.